NYMC Faculty Publications
B-Raf and the Inhibitors: From Bench to Bedside
Author Type(s)
Faculty
DOI
10.1186/1756-8722-6-30
Journal Title
Journal of Hematology & Oncology
First Page
30
Last Page
30
Document Type
Article
Publication Date
4-25-2013
Department
Pathology, Microbiology and Immunology
Keywords
Animals, Cell Line, Tumor, Humans, MAP Kinase Signaling System, Neoplasms, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
Disciplines
Medicine and Health Sciences | Oncology | Pathology
Abstract
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation has been identified and can cause constitutive B-Raf activation. Recent studies have evaluated a variety of small molecule inhibitors targeting B-Raf, including PLX4032/vemurafenib, dabrafenib, LGX818, GDC0879, XL281, ARQ736, PLX3603 (RO5212054), and RAF265. Therapeutic resistance has been identified and various mechanisms described. This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance.
Recommended Citation
Huang, T., Karsy, M., Zhuge, J., Zhong, M., & Liu, D. (2013). B-Raf and the Inhibitors: From Bench to Bedside. Journal of Hematology & Oncology, 6, 30-30. https://doi.org/10.1186/1756-8722-6-30
